A Randomized Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L., Davey, R., et al. (2019). A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England Journal of Medicine. 381:2293-2303.
This article outlines the trial of four investigational Ebola therapies during an outbreak in the DRC in 2018. Patients received monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3. Of the 681 patients enrolled, results showed both MAb114 and REGN-EB3 reduced Ebola-related mortality.